Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hybrid Thoracoscopic-Endocardial Versus Endocardial Catheter Ablation for Persistent Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Journal of arrhythmia·2026

Same author

Effectiveness of three-dimensional printed cardiac models in teaching congenital heart anatomy: A systematic review and meta-analysis of randomized controlled trials.

Anatomical sciences education·2026

Same author

The impact of post-acute sequelae of COVID-19 on cardiac function and structure: A systematic review and a hybrid individual participant data meta-analysis.

American journal of preventive cardiology·2026

Same author

Certainty of Evidence and Procedural Durability of Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: An Umbrella Review of Meta-Analyses.

Cardiology·2026

Same author

Ethanol Infusion in the Vein of Marshall during Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis.

Heart, lung & circulation·2026

Same author

T-Cell-Driven Immunopathology and Fibrotic Remodeling in Hypertrophic Cardiomyopathy: A Translational Scoping Review.

Cells·2026

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

Circulating MicroRNAs and Clinical Parameters in Hypertrophic Cardiomyopathy: A Systematic Review and Correlation

Antonio da Silva Menezes Junior^1,2, Henrique Lima de Oliveira¹, Khissya Beatryz Alves de Lima¹

¹Department of Medicine, Federal University of Goiás, Goiânia, GO 74605-050, Brazil.

Frontiers in Bioscience (Scholar Edition)

|July 7, 2026

Summary

Circulating microRNAs (miRNAs) show significant correlations with cardiac structural and functional changes in hypertrophic cardiomyopathy (HCM). These findings suggest miRNAs may serve as valuable noninvasive biomarkers for HCM, though further research is needed.

Keywords:

biomarkers correlation diagnostic hypertrophic cardiomyopathy microRNA

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Related Experiment Videos

Last Updated: Jul 8, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Area of Science:

Cardiology
Genetics
Biomarker Discovery

Background:

Hypertrophic cardiomyopathy (HCM) is a genetically diverse heart condition.
Left ventricular hypertrophy, myocardial fibrosis, and varied clinical symptoms characterize HCM.
Circulating microRNAs (miRNAs) are potential biomarkers for cardiac remodeling, but their link to specific HCM characteristics is not well understood.

Purpose of the Study:

To systematically review and quantify the association between circulating miRNAs and structural/functional cardiac parameters in HCM.
To explore the potential of miRNAs as noninvasive biomarkers for HCM.

Main Methods:

A systematic review and meta-analysis of 11 observational studies involving 633 patients.
Searched PubMed, Embase, Scopus, and Web of Science databases.
Analyzed correlations between miRNA expression and echocardiography, MRI, and histological data using random-effects models.

Main Results:

Moderate-to-strong positive correlations found between specific miRNAs (miR-21, miR-29a, miR-199a-5p, miR-27a) and myocardial fibrosis, wall thickness, and left ventricular mass (r = 0.53).
Sensitivity and meta-regression analyses confirmed result robustness.
Moderate concerns identified in risk-of-bias assessment, mainly regarding patient selection and blinding.

Conclusions:

Circulating miRNAs are significantly associated with cardiac structural and functional alterations in HCM.
These miRNAs show promise as noninvasive biomarkers for HCM.
High-quality studies are required to confirm their clinical utility.